Skip to main content

Table 1 Patients’ characteristics of PLT-CA125 scores in FIGO stage IV ovarian cancer

From: Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer

Variables Total
(n = 108)
PLT-CA125 score p-valuea
0
(n = 39, %)
1
(n = 48, %)
2
(n = 21, %)
Median age, years (range) 51 (27–75) 51 (33–75) 53 (27–72) 50 (38–69) 0.664
Age, n (%)      0.395
  < 55 64 (59) 19 (49) 25 (52) 14 (54)  
55 44 (41) 20 (51) 23 (48) 7 (46)  
Histology, n (%)      0.709
 HGSC 85 (79) 29 (74) 39 (81) 17 (81)  
 Non-HGSC 23 (21) 10 (26) 9 (49) 4 (19)  
Primary treatment, n (%)      NA
 PDS + chemotherapy 53 (49) 21 (54) 24 (50) 8 (38)  
 NACT+IDS 52 (48) 17 (44) 22 (46) 13 (62)  
 Chemotherapy alone 3 (3) 1 (3) 2 (4) 0 (0)  
Surgery, n (%)      0.760
 Optimal surgery 82 (76) 30 (77) 35 (73) 17 (81)  
Suboptimal surgery/no surgery 26 (24) 9 (23) 13 (27) 4 (19)  
Metastatic pattern, n (%)      0.012
Pleural effusion with positive cytology 17 (16) 5 (13) 7 (15) 5 (24)  
 LNM 44 (41) 10 (26) 21 (44) 13 (62)  
 Other 47 (43) 24 (61) 20 (41) 3 (14)  
Follow up, n, median months (inerquartile range)      NA
 Alive 49 23 20 6  
39.7 (31.7–52.8) 45.7 (36.5–64.8) 37.1 (26.1–52.3) 33.5 (30.6–42.0)  
 Dead 59 16 28 15  
29.0 (19.7–45.3) 37.8 (9.9–64.8) 29.3 (20.0–43.1) 27.4 (19.7–41.7)  
Total 108 39 48 21  
36.6 (23.4–48.1) 45.7 (29.9–64.8) 34.6 (21.9–43.8) 30.6 (24.4–41.2)  
  1. Abbreviations: PLT platelet, HGSC high grade serous carcinoma, Non-HGSC non-high grade serous carcinoma, NA not applicable, PDS primary debulking surgery, NACT neoadjuvant chemotherapy, IDS interval debulking surgery, LNM lymph nodes metastasis beyond abdominopelvic cavity
  2. aTested by one-way ANOVA, Person chi square test or Fisher’s exact test, where applicable